Breakthrough progress made in the development of innovative drugs for hepatitis B domestically.

Recently, the 76th Annual Meeting of the American Association for the Study of Liver Diseases opened in Washington, USA. Breakthrough progress was made in the clinical research of Hepatitis B innovative drug Heppeptide developed by Shanghai Hepu Pharmaceutical. The results of the phase II randomized double-blind clinical trial for the treatment of chronic hepatitis B were announced in the form of a conference report. It was introduced that this innovative drug blocks the unique mechanism of virus entry, and in the phase II clinical trial, it showed the ability to reverse the resistance of "big three-positive" hepatitis B patients to interferon treatment. In some patients, the clearance of cccDNA was achieved, reaching the highest internationally recognized standard for hepatitis B cure - sterilizing cure.